The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.
 
Yizhen Lai
Employment - Evidera; Merck
 
Yichen Zhong
Employment - Merck
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Haojie Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Karl Patterson
No Relationships to Disclose
 
Oliver Hale
No Relationships to Disclose
 
Yang Meng
No Relationships to Disclose
 
Tara L. Frenkl
Employment - Amicus Therapeutics (I); Merck
Leadership - VenatoRx (I)
Stock and Other Ownership Interests - Amicus Therapeutics (I); AstraZeneca; GlaxoSmithKline; Merck
 
James Luke Godwin
Employment - Merck
 
Ronac Mamtani
Consulting or Advisory Role - Genentech/Roche